VCU Massey Cancer Center researchers develop tool for measuring cancer health literacy

NewsGuard 100/100 Score

Virginia Commonwealth University (VCU) Massey Cancer Center researchers have developed the first and only tool that can accurately measure cancer health literacy (CHL) and quickly identify patients with limited CHL. This tool has the potential to improve communication and understanding between physicians and patients, which, in turn, could lead to better clinical outcomes.

Recently published in the Journal of Health Communications, the Cancer Health Literacy Study was conducted over four years and involved 1,306 African-American and Caucasian patients from Massey and surrounding oncology clinics. The researchers developed an evaluation tool called the Cancer Health Literacy Test (CHLT)-30 to measure cancer health literacy along a continuum. The test, which was administered to the patients via a touch-screen device, asked 30 questions about cancer treatment, medication side effects and more. Six of the 30 questions (CHLT-6) were specifically designed to quickly identify individuals with limited CHL. Together, the tests were found to accurately measure CHL and quickly identify patients with limited CHL. This study reported that 18 percent of cancer patients have limited CHL, with an overrepresentation of African-American, undereducated and low-income patients.

"Using this tool, it takes just 1-2 minutes in the doctor's office waiting room to identify patients with limited CHL. Then this information can be digitally communicated to the doctors prior to seeing the patients, so that they are prepared to talk with the patients in terms they can understand," said Levent Dumenci, Ph.D., the study's lead researcher, member of the Cancer Prevention and Control research program at Massey and professor in the Department of Social and Behavioral Health at the VCU School of Medicine. "This simple change could lead to big improvements in health outcomes."

Health literacy is the degree to which individuals have the capacity to obtain, process and understand basic health information and services needed to make appropriate health decisions. "Before now, there were only instruments that measured a particular aspect of general health literacy. It is important to have a tool that is specific to cancer because of the complex treatment options that cancer patients face, along with the increased demand for self-care," says Dumenci.

The demand for increased self-care was emphasized in the Affordable Care Act, where federal and state policymakers embraced patient engagement as a key strategy in addressing health care costs and improving quality of care. Patients are expected to play an active role in their health care by successfully adhering to medication regimens; distinguishing between scientifically credible medical evidence and misconceptions or myths; and effectively communicating with their providers on treatment decisions, risks and survival rates. Patients with limited cancer health literacy can struggle with these responsibilities and potentially jeopardize their health outcomes by making uninformed decisions, mishandling medications and more.

In future studies, the researchers hope to evaluate the CHL of Hispanic patients because prior research has indicated disparities in that population's health literacy.
To do so, the CHL test will need to be translated into Spanish in order to remove the language barrier.

Source:

VCU Massey Cancer Center

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Insilico Medicine's AI-driven approach yields promising PTPN2/N1 inhibitor for cancer immunotherapy